Electrical engineer puts sweat tech to the test
UCLASam Emaminejad has been working on a wearable sensor that can extract sweat by applying an electrical current to the skin and then analyzing its molecular components, such as chloride ions and glucose, to detect certain diseases.Sam Emaminejad, assistant professor of electrical engineering at UCLA, has demonstrated that a wearable biosensor can be used in the diagnosis of cystic fibrosis, diabetes and other diseases by measuring molecules present in an individual's sweat.Hedeveloped the biosensor with colleagueswhile he was a joint postdoctoral researcher at Stanford Medicine and UC Berkeley. Currently, he is completin...
Source: UCLA Newsroom: Health Sciences - April 25, 2017 Category: Universities & Medical Training Source Type: news

Wearable Sensor Collects, Tests Sweat for Cystic Fibrosis, Glucose Levels Wearable Sensor Collects, Tests Sweat for Cystic Fibrosis, Glucose Levels
A next step in wearable health sensors might be a device that causes a patch of skin to sweat, then analyzes the perspiration to monitor or even diagnose disease.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 24, 2017 Category: Pathology Tags: Pathology & Lab Medicine News Source Type: news

Hyperglycemia in Cystic Fibrosis: Is It Diabetes, or Isn't It? Hyperglycemia in Cystic Fibrosis: Is It Diabetes, or Isn't It?
Reporting on the Diabetes UK Professional Conference, Medscape explores the conundrum of hyperglycemia in patients with cystic fibrosis.Medscape Pulmonary Medicine (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - April 24, 2017 Category: Transplant Surgery Tags: Pulmonary Medicine Article Source Type: news

ISHAM Fungal Respiratory Infections in Cystic Fibrosis
Date: Monday, April 24, 2017Year: 2017Location: Osuna, Seville, Spain. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - April 24, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Wearable sensor collects, tests sweat for cystic fibrosis, glucose levels
(Reuters Health) - A next step in wearable health sensors might be a device that causes a patch of skin to sweat, then analyzes the perspiration to monitor or even diagnose disease. (Source: Reuters: Health)
Source: Reuters: Health - April 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

PMD ’s at-home spirometry could improve medication adherence in cystic fibrosis patients
PMD Healthcare touted data today from a pediatric cystic fibrosis study which the company said demonstrates the feasibility of at-home spirometry using its Spiro PD device. Cystic fibrosis patients take a variety of medications daily, PMD pointed out, and adherence to complicated regimens can be a challenge. The Allentown, Penn.-based company’s study examined forced expiratory volume, body mass index and treatment burden scores of the intervention group compared to the control group. Get the full story at our sister site, Drug Delivery Business News. The post PMD’s at-home spirometry could improve med...
Source: Mass Device - April 21, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Patient Monitoring Wall Street Beat pmd healthcare Source Type: news

Wearable sweat sensor can diagnose cystic fibrosis
Stanford University researchers have created a wearable sensor that is capable of diagnosing diseases such as cystic fibrosis by measuring and analyzing sweat. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 20, 2017 Category: Consumer Health News Source Type: news

Asthma news: New drug could revolutionise treatment of breathing disorders
AN EXPERIMENTAL drug could revolutionise the treatment of asthma and other serious breathing disorders - including devastating cystic fibrosis. (Source: Daily Express - Health)
Source: Daily Express - Health - April 18, 2017 Category: Consumer Health News Source Type: news

The FOXM1 inhibitor RCM-1 suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice
Goblet cell metaplasia and excessive mucus secretion associated with asthma, cystic fibrosis, and chronic obstructive pulmonary disease contribute to morbidity and mortality worldwide. We performed a high-throughput screen to identify small molecules targeting a transcriptional network critical for the differentiation of goblet cells in response to allergens. We identified RCM-1, a nontoxic small molecule that inhibited goblet cell metaplasia and excessive mucus production in mice after exposure to allergens. RCM-1 blocked the nuclear localization and increased the proteasomal degradation of Forkhead box M1 (FOXM1), a tran...
Source: Signal Transduction Knowledge Environment - April 18, 2017 Category: Science Authors: Sun, L., Ren, X., Wang, I.-C., Pradhan, A., Zhang, Y., Flood, H. M., Han, B., Whitsett, J. A., Kalin, T. V., Kalinichenko, V. V. Tags: STKE Research Articles Source Type: news

Novel MRI scans could aid in cystic fibrosis
Researchers from the University of Missouri are combining MRI and a form of...Read more on AuntMinnie.comRelated Reading: Advanced visualization tool assesses lung disease CT can replace x-ray for pediatric cystic fibrosis patients Growing radiation dose for CF patients highlights risks MRI used to diagnose complex lung infections in children (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 13, 2017 Category: Radiology Source Type: news

With funding in place, Spyryx CEO focused on Phase 2 trial
After raising $18 million in its Series A round back in 2015, Durham ’s Spyryx Biosciences is currently moving forward with a Phase 2 trial of its drug candidate SPX-101 in cystic fibrosis (CF) patients. Essentially, SPX-101 is designed to regulate airway hydration and enable mucociliary clearance in CF patients, according to the company. It has the potential to b e “applicable to all CF patients,” says Spyryx CEO John Taylor. Since raising $18 million from investors Canaan Partners, Hatteras… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 12, 2017 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

New imaging technique shows effectiveness of cystic fibrosis drug
Cystic fibrosis currently has no cure, though a drug approved by the Food and Drug Administration treats the underlying cause of the disease. However, the drug's effectiveness for each individual is unknown. Researchers have developed an imaging technique using a specific form of helium to measure the drug's effectiveness. Researchers hope the finding could lead to improved therapies for cystic fibrosis and other lung conditions. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 12, 2017 Category: Science Source Type: news

New imaging technique shows effectiveness of cystic fibrosis drug
(University of Missouri-Columbia) Cystic fibrosis currently has no cure, though a drug approved by the Food and Drug Administration treats the underlying cause of the disease. However, the drug's effectiveness for each individual is unknown. Researchers from the University of Missouri School of Medicine have developed an imaging technique using a specific form of helium to measure the drug's effectiveness. Researchers hope the finding could lead to improved therapies for cystic fibrosis and other lung conditions. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 12, 2017 Category: Biology Source Type: news

Peptide Drug Seen as Possible Cystic Fibrosis Tx (CME/CE)
(MedPage Today) -- Polypeptide thymosin alpha-1 fixed molecular defect, cut inflammation (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - April 11, 2017 Category: Pediatrics Source Type: news

Nanoparticles permeate lungs to deliver pulmonary drugs
Researchers from Johns Hopkins University have developed nanoparticles that can shuttle chemicals through the thick mucus membranes of pulmonary airways to deliver drugs. The team’s work was published in the journal Science Advances.  Traditional therapies for cystic fibrosis, COPD and asthma include inhaled corticosteroids that adhere to the walls of air passages. Thick mucus tends to build up inside such passageways, creating a challenge for any delivery system. Get the full story at our sister site, Drug Delivery Business News. The post Nanoparticles permeate lungs to deliver pulmonary drugs ap...
Source: Mass Device - April 11, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Pharmaceuticals Research & Development Respiratory Johns Hopkins Source Type: news

Morrisville CEO talks company growth, timeline for cystic fibrosis treatment
Morrisville-based KNOW Bio ’s respiratory business is moving forward in its fight against antibiotic-resistant pathogens that are all too prevalent for patients with cystic fibrosis (CF) and other lung and respiratory infections. The business has a new name: Novoclem (“the new fight”) Therapeutics. And CEO Anne Whitake r says it could have its lead nitric oxide drug candidate on the market as early as 2021. “We’re really excited about the work that we’re doing and about the potential… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 11, 2017 Category: American Health Authors: Jennifer Henderson Source Type: news

Potential new treatment to treat and stop progression of cystic fibrosis
Researchers have discovered a potential new drug to treat and stop the progression of cystic fibrosis. Thymosin ?1 (T?1) is a novel therapeutic single molecule-based therapy that not only corrects genetic and tissue defects, but also significantly reduces inflammation seen in cystic fibrosis patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 10, 2017 Category: Science Source Type: news

Medical News Today: Potential new treatment for cystic fibrosis uncovered
New research suggests that thymosin alpha 1 can correct the genetic defects typical of cystic fibrosis and stop the progression of the disease. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 10, 2017 Category: Consumer Health News Tags: Cystic Fibrosis Source Type: news

Infection in the cystic fibrosis lung
Wednesday, April 5, 2017 - 12:01Slide presentation (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - April 5, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

New Antibiotic Tx Beneficial After Acute Lung Function Decline in CF
Findings among children with cystic fibrosis treated either inpatient, outpatient (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 5, 2017 Category: Respiratory Medicine Tags: Infections, Nursing, Pediatrics, Pharmacy, Pulmonology, Journal, Source Type: news

Verona commences Phase IIa trial of RPL554 to treat CF
UK-based biopharmaceutical company Verona Pharma has commenced the enrolment and dosing of patients in a Phase IIa clinical trial of RPL554 for the treatment of cystic fibrosis (CF). (Source: Drug Development Technology)
Source: Drug Development Technology - April 5, 2017 Category: Pharmaceuticals Source Type: news

The best (and worst) performing Mass. stocks in March
If you were an investor in Concert Pharmaceuticals in March, you probably did pretty well. That's because the Lexington-based biotech performed better than any other stock this past March, increasing 83 percent in value. Earlier last month, Vertex Pharmaceuticals announced that it would spend $160 million to acquire a once-a-day cystic fibrosis drug for $160 million from Concert. Conce rt wasn't the only biotech stock to see its stock inflate. Click on our slideshow to see the five best-performing… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 3, 2017 Category: Biotechnology Authors: David L. Harris Source Type: news

Lupin, Cipla, other top drugmakers in fray for Novartis ’ brands
The Novartis portfolio includes top-selling brand TOBI Podhaler, a drug prescribed for symptomatic relief to patients suffering from cystic fibrosis, a genetic lung disorder. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 30, 2017 Category: Pharmaceuticals Source Type: news

Corbus drug shows promise as add-on therapy for cystic fibrosis
(Reuters) - An anti-inflammatory drug being developed by Corbus Pharmaceuticals Holdings as an add-on treatment for cystic fibrosis demonstrated promising safety and was well tolerated in a small midstage study, according to data released by the company on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - March 30, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Vertex's tezacaftor shows positive outcome in two Phase III trials to treat CF
US-based biotechnology firm Vertex Pharmaceuticals has reported a positive outcome from two Phase III clinical trials of tezacaftor (VX-661) in combination with ivacaftor to treat cystic fibrosis (CF). (Source: Drug Development Technology)
Source: Drug Development Technology - March 30, 2017 Category: Pharmaceuticals Source Type: news

Duke ’s short lung transplant list saves CF patient
Treatment TermsCystic fibrosisPulmonary rehabilitationLung transplant CategoriesAdvanced treatments SEO Meta Description Cystic fibrosis patient Aimee Driscoll was given just hours to live. With no donor lungs available near her home in Maine, she was flown to Duke. Author MaryAnn Fletcher Overview Cystic fibrosis patient Aimee Driscoll was given just hours to live. With no donor lungs available near her home in Maine, she was flown to Duke. Hero Imageaimee_driscoll_blog.jpg Preview Image Content Blocks Section Header Image/Videoaimee_driscoll_blog2b.jpg Section Features Images/Media Text Content Header Hig...
Source: dukehealth.org: Duke Health News - March 29, 2017 Category: Consumer Health News Authors: mf205 at duke.edu Source Type: news

Vertex gains nearly $4B in market cap on positive cystic fibrosis data
Shares of Vertex Pharmaceuticals surged Tuesday evening after the Boston drugmaker reported positive results from two closely watched trials of a combination treatment for cystic fibrosis, moving the company closer to its goal of treating nearly all patients with the lung disease. Vertex (Nasdaq: VRTX) said that a combination of its blockbuster drug Kalydeco and another cystic fibrosis treatment called tezacaftor had helped patients in both Phase 3 trials improve lung function. Shares of Vertex… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 29, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Vertex hails new cystic fibrosis drug
Combination treatment offers safer option for patients suffering from deadly illness (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - March 29, 2017 Category: Pharmaceuticals Source Type: news

Vertex gains nearly $4B in market cap on positive cystic fibrosis data
Shares of Vertex Pharmaceuticals surged Tuesday evening after the Boston drugmaker reported positive results from two closely watched trials of a combination treatment for cystic fibrosis, moving the company closer to its goal of treating nearly all patients with the lung disease. Vertex (Nasdaq: VRTX) said that a combination of its blockbuster drug Kalydeco and another cystic fibrosis treatment called tezacaftor had helped patients in both Phase 3 trials improve lung function. Shares of Vertex… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 29, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Vertex Seeks Approval for Experimental Cystic-Fibrosis Drug
Vertex Pharmaceuticals said it would seek regulatory approval for one of its experimental cystic-fibrosis drugs after the treatment helped improve patients ’ lung function in late-stage studies. (Source: WSJ.com: Health)
Source: WSJ.com: Health - March 29, 2017 Category: Pharmaceuticals Tags: PAID Source Type: news

Vertex cystic fibrosis combination succeeds in late-stage trials
(Reuters) - Vertex Pharmaceuticals Inc said on Tuesday its Kalydeco cystic fibrosis treatment given with an experimental drug demonstrated significant improvements in lung function in a pair of late-stage trials the company plans to use to seek approval of the combination therapy. (Source: Reuters: Health)
Source: Reuters: Health - March 29, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Vitamins could help treat cystic fibrosis, research finds
Researchers have discovered why antibiotics for treating people with cystic fibrosis are becoming less effective and how fat soluble vitamins might offer a viable solution. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 27, 2017 Category: Science Source Type: news

Genetics reveal mysteries of hard-to-treat bacterial infection in cystic fibrosis
New research on bacteria that cause major problems for those with cystic fibrosis reveals clues as to how it proliferates for so long in the lungs and offers new ideas for treatments to explore. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 27, 2017 Category: Science Source Type: news

Potential of stem cell therapy to repair lung damage
A new study has found that stem cell therapy can reduce lung inflammation in an animal model of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Although, still at a pre-clinical stage, these findings have important potential implications for the future treatment of  patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 27, 2017 Category: Science Source Type: news

Genetics reveal mysteries of hard-to-treat bacterial infection in cystic fibrosis
(University of British Columbia) New UBC research on bacteria that cause major problems for those with cystic fibrosis reveals clues as to how it proliferates for so long in the lungs and offers new ideas for treatments to explore. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 27, 2017 Category: Infectious Diseases Source Type: news

Concert rebuffed $250M buyout offer from Vertex before CF drug deal
Lexington-based Concert Pharmaceuticals rebuffed a $250 million buyout offer from Vertex Pharmaceuticals in November before ultimately striking a deal earlier this month to sell a cystic fibrosis drugs to the Boston company for $160 million, according to a federal filing. The filing on Thursday by Concert (Nasdaq: CNCE) offers new details about the negotiations leading up to its March 6 deal with Vertex(Nasdaq: VRTX). Under the agreement, Vertex is slated to acquire the 69-employee biotech’s cystic… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 24, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Study shows potential of stem cell therapy to repair lung damage
(European Lung Foundation) A new study has found that stem cell therapy can reduce lung inflammation in an animal model of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 24, 2017 Category: Global & Universal Source Type: news

New study resolves the structure of the human protein that causes cystic fibrosis
In order to better understand how genetic mutations give rise to cystic fibrosis, researchers need to map the protein responsible for the disorder. The new structure has led to new insights on how this molecular channel functions. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 23, 2017 Category: Science Source Type: news

New study resolves the structure of the human protein that causes cystic fibrosis
In order to better understand how genetic mutations give rise to cystic fibrosis, researchers need to map the protein responsible for the disorder. The new structure has led to new insights on how this molecular channel functions. More » (Source: The Rockefeller University Newswire)
Source: The Rockefeller University Newswire - March 23, 2017 Category: Biomedical Science Authors: Wynne Perry Tags: Science News CFTR cystic fibrosis David C. Gadsby Jue Chen Laboratory of Cardiac and Membrane Physiology Laboratory of Membrane Biology and Biophysics structural and chemical biology Source Type: news

Tackling a Decade of Change
There has never been a more exciting time to be in the pharmaceutical industry – if you like change, that is. While change is a constant in business, pharma has experienced unprecedented levels over the past decade, says Alistair Grenfell, President, North Europe, Middle East and Africa, at QuintilesIMS.“At a time when we are seeing a huge amount of innovation in our science and our pipeline – creating great excitement among the healthcare community – we need to acknowledge that our world has changed,” says Grenfell. “If you wind the clock back to 2005 and look at the top 10 selling medi...
Source: EyeForPharma - March 23, 2017 Category: Pharmaceuticals Authors: Hugh Gosling Source Type: news

New study resolves the structure of the human protein that causes cystic fibrosis
(Rockefeller University) In order to better understand how genetic mutations give rise to cystic fibrosis, researchers need to map the protein responsible for the disorder. The new structure has led to new insights on how this molecular channel functions. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 23, 2017 Category: Biology Source Type: news

Galapagos begins Phase I trial of GLPG0367 to treat cystic fibrosis
Belgium-based biopharmaceutical firm Galapagos has begun the Phase I clinical trial of GLPG3067 for the treatment of patients with cystic fibrosis (CF). (Source: Drug Development Technology)
Source: Drug Development Technology - March 23, 2017 Category: Pharmaceuticals Source Type: news

From Genome Research: Pathogen demonstrates genome flexibility in cystic fibrosis
(Cold Spring Harbor Laboratory) Chronic lung infections can be devastating for patients with cystic fibrosis (CF), and infection by Burkholderia cenocepacia, one of the most common species found in cystic fibrosis patients, is often antibiotic resistant. In a study published today in Genome Research, scientists sequenced and phenotyped multiple B. cenocepacia isolates from 16 CF patients. They found extensive variation among isolates during chronic lung infection as well as changes in clinically relevant bacterial phenotypes. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 21, 2017 Category: Infectious Diseases Source Type: news

PodMed: A Medical News Roundup From Johns Hopkins (with audio)
(MedPage Today) -- This week's topics include managing after DVT, anticoagulation in folks with Afib, surviving with cystic fibrosis, and where to have rehabilitation after knee replacement. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - March 18, 2017 Category: Pediatrics Source Type: news

Canadians With Cystic Fibrosis Live 10 Years Longer Than Americans With the Disease
Canadians with cystic fibrosis survive on average more than 10 years longer than Americans with the disease. Health insurance differences may be why. (Source: NYT Health)
Source: NYT Health - March 15, 2017 Category: Consumer Health News Authors: NICHOLAS BAKALAR Tags: Cystic Fibrosis Health Insurance and Managed Care Transplants Medicare Source Type: news

Cystic Fibrosis Patients in Canada Live Longer Than Those in U.S.
Canadians with cystic fibrosis live about 10 years longer on average, researchers say (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 15, 2017 Category: Respiratory Medicine Tags: Family Medicine, Internal Medicine, Nursing, Pathology, Pediatrics, Pulmonology, Journal, Source Type: news

Cystic Fibrosis Survival Better in Canada Than in U.S.
Canadians with the lung disease live about 10 years longer on average, study finds Source: HealthDay Related MedlinePlus Page: Cystic Fibrosis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 14, 2017 Category: Consumer Health News Source Type: news

Cystic Fibrosis Survival Better in Canada Than in U.S.
Title: Cystic Fibrosis Survival Better in Canada Than in U.S.Category: Health NewsCreated: 3/13/2017 12:00:00 AMLast Editorial Review: 3/14/2017 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - March 14, 2017 Category: Respiratory Medicine Source Type: news

Cystic Fibrosis Survival Better in Canada Than in U.S.
Canadians with the lung disease live about 10 years longer on average, study finds (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 14, 2017 Category: Respiratory Medicine Authors: webmaster at doctorslounge.com Tags: Family Medicine, Nursing, Pulmonology, Nutrition, Organ Transplants, News, Source Type: news